Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Fibroblast Growth Factor Receptor”

72 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 72 results

Testing effectiveness (Phase 2)UnknownNCT05019794
What this trial is testing

Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaSolid Tumor
LianBio LLC 80
Early research (Phase 1)Study completedNCT01976741
What this trial is testing

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Who this might be right for
Neoplasms
Bayer 168
Not applicableStudy completedNCT04035811
What this trial is testing

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 271
Testing effectiveness (Phase 2)Ended earlyNCT03822117
What this trial is testing

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Who this might be right for
Solid Tumor Malignancy
Incyte Corporation 111
Large-scale testing (Phase 3)Ended earlyNCT04197986
What this trial is testing

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Who this might be right for
Upper Tract Urothelial CarcinomasUrothelial Bladder Cancer
QED Therapeutics, a BridgeBio company 39
Early research (Phase 1)Ended earlyNCT02368951
What this trial is testing

Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

Who this might be right for
Medical Oncology
Bayer 20
Testing effectiveness (Phase 2)Study completedNCT05529667
What this trial is testing

Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.

Who this might be right for
Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel
Yonsei University 15
Large-scale testing (Phase 3)Ended earlyNCT03656536
What this trial is testing

Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

Who this might be right for
Unresectable CholangiocarcinomaMetastatic Cholangiocarcinoma
Incyte Corporation 167
Testing effectiveness (Phase 2)Ended earlyNCT01367275
What this trial is testing

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

Who this might be right for
Colorectal CancerColorectal Adenocarcinoma
M.D. Anderson Cancer Center 8
Testing effectiveness (Phase 2)Looking for participantsNCT07292168
What this trial is testing

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

Who this might be right for
Renal Cell Carcinoma MetastaticProstate Cancer MetastaticNon-small Cell Lung Cancer Metastatic+2 more
Kidney Cancer Research Bureau 58
Not applicableLooking for participantsNCT06410976
What this trial is testing

Prospective Clinical Assessment Study in Children With Hypochondroplasia

Who this might be right for
Hypochondroplasia
QED Therapeutics, a BridgeBio company 150
Testing effectiveness (Phase 2)WithdrawnNCT02747797
What this trial is testing

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

Who this might be right for
Advanced Cancer
Teresa Helsten, MD
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05145010
What this trial is testing

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 300
Early research (Phase 1)Study completedNCT03235570
What this trial is testing

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

Who this might be right for
Solid Tumors
Incyte Corporation 44
Testing effectiveness (Phase 2)UnknownNCT06022289
What this trial is testing

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Who this might be right for
Solid TumorFGF Receptor Gene MutationFGF Amplification+2 more
Tianjin Medical University Second Hospital 20
Early research (Phase 1)Looking for participantsNCT06625593
What this trial is testing

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
BeOne Medicines 168
Testing effectiveness (Phase 2)Study completedNCT02053636
What this trial is testing

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Institut de Recherches Internationales Servier 76
Testing effectiveness (Phase 2)Study completedNCT01719549
What this trial is testing

Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

Who this might be right for
Gastric Cancer
Asan Medical Center 19
Testing effectiveness (Phase 2)Ended earlyNCT04604132
What this trial is testing

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
Basilea Pharmaceutica 47
Testing effectiveness (Phase 2)Looking for participantsNCT06511648
What this trial is testing

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Who this might be right for
Muscle-invasive Bladder Cancer
Spanish Oncology Genito-Urinary Group 90
Load More Results